Atrial fibrillation and reninangiotensinaldosterone system: Believe it or not

Europace

Volumn 13, Issue 3, 2011, Pages 297-298

  Fauchier, Laurent ^a   De Groote, Pascal ^b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARRHYTHMOGENESIS; EDITORIAL; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; GENETICS; INDEL MUTATION; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; HUMANS; INDEL MUTATION; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 79952162041     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq451     Document Type: Editorial

References (14)

1. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9. (Pubitemid 40789940)
2. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299-307.
3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31: 2369-429.
4. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP et al. GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-17.
5. Goette A. ANTIPAF: angiotensin II-antagonist in paroxysmal atrial fibrillation trial. Presented at the European Society of Cardiology (ESC) Congress 2010. http:// www.escardio.org/congresses/esc-2010/congress-reports/ pages/708-5-antipaf.aspx (5 December 2010, date last accessed).
6. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27:512-8.
7. Iravanian S, Dudley CS. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 2008;5:S12-7.
8. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006;98:1123-33. (Pubitemid 43948098)
9. Andalib A, Brugada R, Nattel S. Atrial fibrillation: evidence for genetically determined disease. Curr Opin Cardiol 2008;23:176-83. (Pubitemid 351489319)
10. van den Berg MP, Van Gelder IC. New insight into the association among atrial fibrillation, electrophysiological remodeling, and the ACE insertion/deletion polymorphism- toward a more patient-tailored therapy? Heart Rhythm 2009;6: 1333-4.
11. Liu T, Korantzopoulos P, Xu G, Shehata M, Li D, Wang X et al. Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis. Europace 2011;13:346-354.
12. Watanabe H, Kaiser DW, Makino S, MacRae CA, Ellinor PT, Wasserman BS et al. ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. Heart Rhythm 2009;6:1327-32.
13. Gillis AM. Angiotensin-receptor blockers for prevention of atrial fibrillation-a matter of timing or target? N Engl J Med 2009;360:1669-71.
14. Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwöhner M, Strugala D et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008;117:732-42. (Pubitemid 351640674)